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publications are not available. With respect to the progress of benefit assessment and 
the subsequent price negotiation it would be helpful having alternatives with accept-
able properties in order to estimate the extent of additional benefit.
PRM220
The Use of InTeRqUaRTIle DevIaTIon In esTablIshIng DelPhI Panel 
ConsensUs: a PRIoRITIzaTIon of InTRavenoUs IMMUnoglobUlIn 
UTIlIzaTIon
Orange J1, Lennert B2, Rane P3, Eaddy M2
1Texas Children’s Hospital, Houston, TX, USA, 2Xcenda, Palm Harbor, FL, USA, 3University of 
Houston, Houston, TX, USA
Objectives: To use consensus-building methodologies to prioritize disease 
states for intravenous immunoglobulin (IVIG) utilization while considering dis-
ease severity and alternative therapeutic options. MethOds: A 7-member expert 
panel independently ranked 50 disease states across 2 domains: (1) Disease sever-
ity (DS) (1= immediately life-threatening, 2= life-threatening, 3= life-modifying, 
4= other) and (2) the perceived efficacy of therapeutic alternatives (TA) (1= none, 
2= low, 3= medium, 4= high). An interquartile deviation of ≤ 0.5 was used to deter-
mine consensus for disease states within each domain. Disease states reaching 
consensus across both domains were ranked according to a 4x4 algorithmic scale 
to establish priority. Results: The panel reached consensus on the severity of all 
diseases states; however, 11 of the 50 disease states did not reach consensus on 
the availability of alternative therapeutic options. No disease state was designated 
as being immediately life-threatening without an available alternative therapeu-
tic option (DS1TA1), while 3 disease states (X-linked agammaglobulinemia, com-
mon variable immunodeficiency, primary immunodeficiency with absent B-cells) 
were designated as life-threatening with no therapeutic alternatives (DS2TA1). The 
priority distribution of disorders based on the algorithm is as follows: DS1TA1= 0, 
DS1TA2= 1, DS1TA3= 1, DS1TA4= 1 DS2TA1= 3, DS2TA2= 4, DS2TA3= 3, DS2TA4= 1 
DS3TA1= 0, DS3TA2= 7, DS3TA3= 14, DS3TA4= 0 DS4TA1= 0, DS4TA2= 0, DS4TA3= 3, 
DS4TA4= 1 cOnclusiOns: The application of interquartile deviation in establishing 
consensus across two 4-point Likert scales resulted in prioritizing 80% of disease 
states where IVIG can be used. Additional consensus-building rounds will be needed 
to prioritize the remaining disease states.
PRM221
neTwoRk MeTa-analysIs foR healTh TeChnology sUbMIssIons 
woRlDwIDe: a RePoRT CheCklIsT foR neTwoRk MeTa analysIs besT 
PRaCTICes globally
Batson S, Greenall G
Abacus International, Oxfordshire, UK
Objectives: Network meta-analysis (NMA) represents an important and develop-
ing method for Health Technology Assessment (HTA). The aim of this study was 
to review submission guidelines issued by HTA bodies worldwide and produce 
a checklist for reporting NMA within HTA submissions globally. MethOds: The 
web-based repository of country-specific pharmacoeconomic guidelines maintained 
by ISPOR was reviewed in January 2015. Guidelines from a number of countries 
providing sufficient guidance for the use of NMA in HTA submissions were iden-
tified and independently reviewed. Results: Following review of the available 
guidance from a number of countries, a single common checklist was developed. 
The checklist included recommendations relating to five main themes: data; sta-
tistical methodology; analyses performed; presentation of results; and technical 
issues. cOnclusiOns: This reporting checklist provides practical support to health 
technology manufacturers enabling them to assess the suitability of NMA reports 
in meeting the requirements of global HTA bodies. In addition, this checklist can be 
seen as a valid quality tool to critically appraise the reporting of NMAs within HTA.
ReseaRCh on MeThoDs – study Design
PRM222
TRansPaRenCy anD RePRoDUCIbIlITy of sUPPleMenTaRy seaRCh 
MeThoDs In nICe sIngle TeChnology aPPRaIsal ManUfaCTUReR 
sUbMIssIons
Witkowski MA, Aldhouse N
Abacus International, Bicester, UK
Objectives: Systematic reviews (SRs) form an important part of National Institute 
for Health and Care Excellence (NICE) single technology appraisal (STA) manufac-
turer submissions. To minimise publication bias when conducting SRs, supple-
mentary searches should be conducted, and should follow the same principles 
of transparency and reproducibility as database searches. This study aimed to 
evaluate supplementary search methods used in NICE STA manufacturer submis-
sions. MethOds: NICE STAs published between 2011 and 2015 were reviewed. 
Supplementary search details from manufacturer submissions and related critique 
from corresponding evidence review group (ERG) reports were extracted. Searches 
were deemed reproducible if the minimum amount of information required to repro-
duce searches was reported. Results: Of 126 STAs identified, 80 were excluded: 
appraisal reviews/updates (n= 20); appraisal terminated (n= 12); no full submission 
available (n= 9); appendices (containing search methods) not published online 
(n= 39). Of 46 included manufacturer submissions, 28 reported conference searches, 
of which 24 provided enough information for searches to be reproduced. Twenty-one 
reported clinical trials registry searches, but only seven provided enough informa-
tion to reproduce these. Thirty-six reported conducting other manual searches, 
including: manufacturer internal databases (n= 24); reference lists (n= 20); regulatory 
body websites (n= 11); other websites (n= 5); internal experts (n= 2). Evidence review 
groups critiqued omission of supplementary searches in 8 of 18 submissions which 
lacked searches of conference proceedings, and in 8 of 25 submissions which did not 
report searching clinical trial registries. The evaluation methods differed between 
ERGs. cOnclusiOns: Principles of transparency and reproducibility were not fol-
PRM217
The Use of PRoPensITy sCoRe MaTChIng Does noT PRoTeCT agaInsT 
RegRessIon aRTIfaCTs (RegRessIon TowaRDs The Mean)
Caron C1, Wasser T2, Eisenberg D2
1Reading Hospital, West Reading, PA, USA, 2HealthCore Inc., Wilmington, DE, USA
Objectives: Propensity Score Matching (PSM) is a common method in many 
retrospective studies to control for differential treatments. PSM controls for vari-
ables where patients are selected for one treatment over another based on aspects 
of their care that are unknown to the researcher or not a part of the study. This 
study uses simulated data comparing two cohorts within a population treated 
for a common psychiatric disorder. Data are analyzed to determine if regression 
artifacts (RA) are present in the data, uncontrolled by PSM. RA in this context are 
Type I errors. MethOds: Variables commonly used to diagnose patients with 
Major Depression were simulated: Age, Gender, Ethnicity, Global Assessment of 
Functioning, Beck Depression and Beck Anxiety scores. Distributions of N= 100,000 
were simulated for each variable using population values. From these distribu-
tions, samples of n= 100, n= 250 and n= 500 were drawn based on typical values 
that would be seen in a patient with Major Depression. The outcome measure 
Dependent Variable was the score on the Beck Depression scale, using success of 
treatment values from 10-15 percent, and correlated with the pretest score using 
Chomsky’s decomposition. PSM was used on a ratio of 1:1. Analysis methods were 
group and paired t-tests as well as a difference in difference analysis at the end of 
the study. Results: Type I error occurred in each simulation and were correlated 
with sample size. RA, leading to Type I error were more common at lower sample 
sizes, in excess of 70%, to a minimum of 54% for n= 500. cOnclusiOns: This study 
demonstrates that RA occur in basic experiments designed to specify treatment 
effects. Researchers who use PSM methods need to be aware of situations where 
RA are likely to occur. Standard statistical controls for RA are being tested to see if 
they correct for RA and Type I error when PSM is used.
PRM218
aPPlICaTIon of sIMPle IMPUTaTIon TeChnIqUes foR MIssIng PaIRwIse 
ConTRasTs fRoM MUlTI-aRM TRIals when UsIng fReqUenTIsT neTwoRk 
MeTa analysIs
Petto H1, Brnabic A2, Kadziola Z1, Belger M3
1Eli Lilly Regional Operations GmbH, Vienna, Austria, 2Eli Lilly, Sydney, Australia, 3Eli Lilly and 
Company Ltd, Windlesham, UK
Objectives: When conducting frequentist (fixed effects or random effects) network 
meta-analysis (NMA), input data is usually required in contrast form. In practice, 
multiple-arm trials are quite common and results for only the contrast relative to 
one treatment group are presented. However, some frequentist NMA require all 
possible pairwise treatment effects and standard errors combinations. While the 
missing effect sizes can still be directly derived, additional assumptions about co-
variances are needed to calculate standard errors. MethOds: Simple imputation 
techniques are used for substituting the standard errors of the missing comparisons 
and this has been applied to both simulated data as well as a real world data exam-
ple. After imputation data is analyzed using standard frequentist NMA, incorporat-
ing multi arm studies by the method described in Rücker (2015). Results: We derive 
simple imputations techniques by (1) assuming independence between contrasts, 
(2) estimating missing co-variances from the available contrasts in the multi arm 
trials and (3) from the other two arm studies in the network. Comparable results 
to networks including all pairwise contrasts can be obtained, especially if only few 
contrasts are missing in multi arm studies and if variances of the comparisons are 
not too different. In the first case, even (1) can give acceptable results. If variances 
differ, but are similar to that from two arm studies then (3) might be preferable over 
(2). cOnclusiOns: Our results suggests that from a practical point of view, simple 
imputation techniques might be useful tools for incorporating multi arm trials with 
incomplete pairwise contrasts into frequentist NMA, although limitations need to 
be carefully considered. Rücker G: Network meta-analysis, electrical networks and 
graph theory. Research Synthesis Methods, 2012, 3, 312–324.
PRM219
InDIReCT CoMPaRIsons In benefIT assessMenT
Kühnast S1, Schiffner-Rohe J2, Rahnenführer J1, Leverkus F2
1Technical University of Dortmund, Dortmund, Germany, 2Pfizer Deutschland GmbH, Berlin, 
Germany
Objectives: With the Act on the Reform of the Market for Medicinal Products 
(AMNOG) in Germany, pharmaceutical entrepreneurs must submit a dossier dem-
onstrating additional benefit of a new drug compared to an appropriate comparator. 
Underlying evidence was planned for registration purposes and therefore often does 
not meet the appropriate comparator as defined by the Federal Joint Committee 
(G-BA). For this reason AMNOG allows indirect comparisons (ICs) to assess the 
extent of additional benefit. This study evaluates the applicability of available IC 
methods in several situations common to benefit assessment in oncological indi-
cations. MethOds: An extensive literature search on available statistical methods 
for performing ICs is performed. Additionally, benefit dossiers containing ICs are 
analyzed regarding the applied methodology. We use simulation studies to evaluate 
and compare adjusted (Bucher) and unadjusted methods regarding their properties 
under different circumstances. Results: Adjusted ICs are deemed to be “state of the 
art”. Due to their requirements they are, nevertheless, often not applicable. In most 
cases reasons are lacking comparability of the trials, e.g. concerning the common 
comparator, the study population and the study design.Simulations of Hazard Ratios 
for endpoints overall survival and progression free survival were performed consider-
ing various “extents of additional benefit” according to IQWiG criteria. Starting with a 
setting of identical studies we stepwise modified study population and various attrib-
utes in study design. Finally the common comparator was omitted. Discrepancies 
between ICs and true values are compared graphically and on the basis of statistical 
measures. cOnclusiOns: ICs imply a set of requirements to be able to derive valid 
statements. Prerequisites for adjusted ICs are often not met as necessary studies and 
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were identified. After removing duplicates, 1,525 citations were screened. Of these, 
159 full text references were reviewed and 85 systematic reviews met predefined 
inclusion criteria. Five QA methods were most commonly employed: Newcastle-
Ottawa Quality Assessment Scale (NOS) or modified NOS (28%); checklists devel-
oped by authors (15%); the Cochrane checklist or modified version (11%); modified 
checklists from other authors (5%); applying disease-specific QA tools (5%). The 
reliability and applicability of the most commonly employed tool in this research 
field, NOS, were questioned in included reviews, corresponding with concerns on the 
validity of the NOS reported in recently published literature of research methodol-
ogy. cOnclusiOns: The available evidence demonstrates a lack of consensus on 
the use of QA tools for non-RCTs assessing surgical interventions. Various methods 
have been adapted or newly developed by researchers, and the most commonly 
applied QA tool (NOS) may not be fit for purpose in this field of research. There is 
an urgent need for a validated QA tool to appraise the quality of evidence to help 
inform evidence-based decision making on the use of surgical devices and types 
of surgical approaches.
PRM226
InCIDenCe anD PRevalenCe esTIMaTIons baseD on ClaIMs DaTa – new 
MeThoDologICal ConsIDeRaTIons
Prosser C1, Altevers J1, Hickstein L2, Walker J2, Braun S1
1Xcenda GmbH, Hannover, Germany, 2Elsevier Health Analytics, Health Risk Institute, Berlin, 
Germany
Objectives: Scientific analyses with claims data such as burden of disease analyses 
are often based on incidence and prevalence estimates. Latest methodological con-
siderations indicate that the diagnosis-free observation period should be extended 
as much as possible to not overestimate the incidence in chronic diseases. Aim of 
this study was to evaluate the impact of expanding the diagnosis timeframe for 
the incidence as well as the prevalence estimates. MethOds: This methodologi-
cal analysis focused on the chronic diseases diabetes mellitus (DM) and multiple 
sclerosis (MS) in 2013 in Germany and was based on anonymized data from the 
Health Risk Institute Research Database. Patients continuously insured for six years 
(2008-2013) were included in the study (n= 3,026,154). Incidence changes due to dif-
ferent diagnosis-free intervals before a diagnosis in 2013 (1 to 5 years) were assessed. 
Correspondingly, the prevalence estimation for 2013 was varied by expanding the 
timeframe for diagnosis from 1 year up to 5 years, as it was assumed that chronic 
diseases identified in previous years persist until 2013. Moreover, disease-specific 
validation of the diagnosis codes was applied as sensitivity analysis. Results: DM 
incidence was 24% higher when a 1-year diagnosis-free observation period was 
applied compared to 5 years (25% in MS). When expanding the prevalence timeframe 
up to 5 years, the prevalence estimation increased by 14% in DM and 21% in MS, 
respectively. The relative proportion of incidence to prevalence also changed by 
varying the utilized timeframe. Out of the prevalent diabetes patients in 2013 10.1% 
were incident when a 1-year timeframe was considered, whereas 7.3% were incident 
when 5 years were applied (11.7% and 7.9% in MS, respectively). cOnclusiOns: 
The methodological concepts should coincide when estimating both the incidence 
and the prevalence of chronic diseases in claims data. Estimates may be biased 
especially when only short timeframes are utilized.
PRM227
sTaTIsTICal assessMenT of a Case-fInDIng algoRIThM foR IDenTIfyIng 
non-sMall Cell lUng CanCeR (nsClC) PaTIenTs In aDMInIsTRaTIve 
ClaIMs DaTabases
Turner RM1, Croft E2, Chen Y1, Tunceli O3, Elesinmogun C2, Fernandes A2
1HealthCore, Wilmington, DE, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3HealthCore Inc., 
Wilmington, DE, USA
Objectives: The ICD-9-CM coding system does not differentiate between small cell 
lung cancers (SCLC) and NSCLC, which poses a challenge for database research on 
forms of lung cancer. We examined the accuracy of an algorithm designed to identify 
likely NSCLC cases among lung cancer patients in a claims-database. MethOds: 
Lung cancer patients were selected from the HealthCore Integrated Research 
Environment (HIRE)-Oncology database which combines US administrative claims 
database, and the clinical oncology data (type, stage, etc.) on lung cancer patients. 
Index event was defined as the patient’s first lung cancer diagnosis during 6/1/14 
to 1/31/15 in the claims database. Eligibility criteria were; ≥ 1 lung cancer diagnosis 
& > 12 months continuous pre-index enrolment in the claims database; and pres-
ence in the oncology database. A treatment regimen algorithm was used to iden-
tify NSCLC patients from claims data. This was assessed against the cancer type 
information from the oncology database. Diagnostic accuracy of the algorithm was 
assessed using statistical measures; Sensitivity, Specificity, False Positive Fraction 
(FPF), Positive Predictive Validity (PPV), Negative Predictive Validity (NPV), Positive 
Likelihood Ratio (LR+), Negative Likelihood Ratio (LR-), Diagnostic Odds Ratio (DOR), 
and Agreement (kappa:k). Results: 585 lung cancer patients (mean age = 62, 53% 
male) met all eligibility criteria for analysis. The algorithm classified 464 (79%) 
patients as NSCLC and 121 (21%) as SCLC; whereas, the clinical data classified 513 
(88%) patients as NSCLC and 72 (12%) as SCLC. Algorithm sensitivity was 86% and 
specificity was 71%. The FPF = .29%, PPV= 96%, and NPV= 42%. LR+ = 2.96; LR- = 0.19; 
and DOR= 15.37. Chance adjusted k = .60. cOnclusiOns: The algorithm showed 
good statistical properties for identifying NSCLC patients in claims data except 
for a high false positive fraction. Future research should focus on improving the 
algorithm’s specificity.
PRM228
sysTeMaTIC lITeRaTURe RevIew of aDjUnCTIve anTI-ePIlePTIC DRUg 
TRIals In PaTIenTs wITh PRIMaRy geneRalIzeD TonIC-ClonIC seIzURes 
IllUsTRaTes Changes In sTanDaRD of CaRe oveR 12-20 yeaRs
Tsong WH1, Gomez-Ulloa D2, Li H3, Forsythe A1, Kramer L1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2IMS Health, Barcelona, Spain, 3IMS Health, Alexandria, VA, 
USA
lowed in the majority of manufacturer submissions where supplementary searches 
were conducted. However, the results from this study are limited due to the low 
number of appendices published online. Supplementary search methods used in 
manufacturer submissions should be reported in full and ERGs should be consist-
ent with critique of supplementary search methodology to ensure no evidence is 
omitted in decision making.
PRM223
InCReasIng PReCIsIon of Real-woRlD DaTa esTIMaTes: The IMPoRTanCe 
of a sTeP-wIse PRoCess To lIMIT DaTa ColleCTIon eRRoRs anD DaTa 
InCoMPleTeness
Kritikou P1, de Cock E2, Stein D3
1United BioSource Corporation, London, UK, 2UBC: An Express Scripts Company, London, UK, 
3UBC: An Express Scripts Company, Dorval, QC, Canada
Objectives: Create a step-wise process to mitigate data collection errors and miss-
ing data during all phases of prospective and retrospective observational stud-
ies. MethOds: Based on three multinational retrospective chart review studies 
and two multinational time and motion (T&M) studies completed in 2015, key fac-
tors were identified during all study phases (design, implementation, conduct, and 
analysis) that could lead to data collection errors and missing data. For both meth-
odologies, we designed a step-wise process to help identify risk factors and provide 
effective solutions to improve data quality. Results: During study design, study 
variables should unequivocally be defined with terminology/semantics matching 
the source document (e.g., medical chart) or what is observed in the real-world. 
Differences between countries need to be considered. Training using real-time dem-
onstration of electronic data collection (EDC) tool using examples of de-identified 
patient data is critical for chart reviews. For T&M studies, observers must be trained 
on accurate data measurement and recording. For a chart review using an EDC 
tool, logic and edit checks should be built into the EDC tool to limit data errors and 
incomplete data at entry. For a T&M design, speed of data transmission and fast 
quality control is essential to allow recall by the data observer. Queries for missing 
data or outliers should be phrased objectively and clearly. Effectiveness of quality 
control mechanisms needs to be assessed particularly at the start of data collection, 
and retraining performed, if needed. cOnclusiOns: Limiting data collection errors 
and data incompleteness starts at study design. Essential components of a step-wise 
process include appropriate variable selection and description (terminology/seman-
tics), (re)training, and tailored quality control mechanisms. If such steps are fol-
lowed, data collected would result in a more accurate dataset, therefore improving 
the overall quality of study data and precision of study results.
PRM224
a CoMPRehensIve DIsease MoDel of PolyCysTIC ovaRy synDRoMe (PCos)
Eek D1, Paty J2, Black P3, Celeste Elash CA3, Reaney M4
1Astra Zeneca, Molndal, Sweden, 2Quintiles, Hawthorne, NY, USA, 3ERT, Pittsburgh, PA, USA, 
4ERT, Peterborough, UK
Objectives: Polycystic ovary syndrome (PCOS) is one of the most common female 
endocrine disorders. It presents with a broad range of symptoms and has significant 
and diverse clinical implications. In order to develop a comprehensive understand-
ing of PCOS, a (conceptual) disease model was developed. MethOds: The disease 
model was generated based on three lines of concept evaluation research; (1) a 
targeted literature review, (2) interviews with clinical experts; (3) concept elicita-
tion interviews with patients, for which data was recorded, transcribed and coded. 
Collectively, this provided a comprehensive list of the sign, symptom and impact 
concepts most important and relevant to women with PCOS. Results: Nineteen 
peer-reviewed articles were included in the literature review. Five clinical experts 
(USA, Turkey, Netherlands) and 20 PCOS patients (mean (SD) age 29.2 (5.9) years) were 
included in 1:1 qualitative interviews. Concept saturation was observed in patient 
interviews. Significant overlap was seen in the sign, symptom and impact concepts 
of PCOS across the three lines of evidence. Signs/symptoms were categorized into 
pain, infertility, hirsutism, alopecia, acne, menstruation (e.g. irregular menstrua-
tion, heavy bleeding), bloating, weight-related (e.g. weight gain, fluctuations), and 
metabolic abnormality (i.e., obesity, difficulty with weight loss, etc) symptoms. 
Some symptoms, such as pain at non-menstrual times, were uniquely reported 
by patients. Impacts of PCOS included sleep disturbance, emotional functioning, 
social role functioning and physical functioning. Compensatory behaviours (e.g. hair 
removal, diet changes, use of medication) were common. The relationship between 
these concepts is presented in a disease model. cOnclusiOns: This is the first 
known comprehensive disease model for PCOS. It shows many of the defining fea-
tures of the condition can only be accurately and reliably captured by asking patients 
how they feel and function. This work underscores the need for measurement of 
PCOS from the patient perspective using a patient reported outcome (PRO).
PRM225
evalUaTIon of qUalITy assessMenT Tools foR non-RanDoMIseD 
ConTRolleD TRIals assessIng sURgICal InTeRvenTIons: a sysTeMaTIC 
RevIew of sysTeMaTIC RevIews
Nurmatov UB, Xiong T, Kroes MA
Abacus International, Bicester, UK
Objectives: Evaluating the effectiveness and safety of surgical techniques, opera-
tions, and involved medical devices is relatively difficult, sometimes unethical, 
with randomised controlled trials (RCTs). Non-randomised designs are commonly 
applied and used to inform decision making. Quality assessment (QA) methods for 
these studies have previously been reviewed, but not specifically for their appli-
cability to non-RCTs in surgical interventions. The objectives of this systematic 
review were to evaluate which QA tools have been used in this research field and to 
critically appraise these tools. MethOds: We systematically searched three elec-
tronic databases (MEDLINE, Embase and Cochrane Library) and Health Technology 
Assessments. Systematic reviews appraising the quality of non-RCTs on surgical 
interventions were included. Results: In total, 1,741 potentially relevant citations 
